Karachi: Rizwan Ahmad, the Executive Director of Citi Pharma Limited, has executed a significant transaction involving the sale of company shares, as per the disclosure made under Pakistan Stock Exchange (PSX) Regulation 5.6.4. The transaction details were released to inform stakeholders about changes in shareholding by key personnel and their close relations.

According to the statement dated March 26, 2025, Ahmad sold 240,000 shares of Citi Pharma Limited at a rate of 86.51 per share. This transaction leaves him with a cumulative total of 45,749,934 shares, which constitutes a 20.02% holding in the company. The transaction was conducted through the Central Depository Company (CDC) under the ready market form of share certificate.

The disclosure is part of regulatory requirements to ensure transparency and maintain investor confidence in the market. Such disclosures provide insights into the actions of significant shareholders and executives within publicly traded companies.

According to information available from the Pakistan Stock Exchange (PSX), the transaction by Ahmad highlights the movement within the executive ranks of Citi Pharma Limited, a company listed in the healthcare sector of the designated market category. The sale of shares by a key executive may influence market perceptions and investor decisions regarding the company’s future prospects.

The regulatory framework mandates that any transactions by directors or substantial shareholders, along with their immediate family members, must be disclosed to ensure that all stakeholders have access to pertinent information regarding insider activities.